Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)
Clinical trial NCT04330625 · TERMINATED
Trial details
- NCT number
- NCT04330625
- Sponsor
- Duke University
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-13
- Primary completion
- 2021-05-05
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.